Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• Gallbladder cancer (GBC) has a poor prognosis with limited effective treatments.
• Hedgehog (Hh) signaling is implicated in various cancers and presents a potential therapeutic avenue.
• The role of Hh signaling in GBC pathogenesis remains largely unexplored.

Purpose of the Study:

• To investigate the biological significance of Hh signaling in human GBC.
• To determine if Hh signaling could serve as a viable therapeutic target for GBC.

Main Methods:

• Assessed Hh pathway activation by detecting Gli1 nuclear localization in GBC cells versus normal cells.
• Quantified expression levels of Sonic Hh (Shh) and Smoothened (Smo) in GBC tissues and normal gallbladder tissue.
• Utilized in vitro assays to evaluate the effects of Shh ligand and Smo inhibition on GBC cell proliferation and invasiveness.
• Examined the impact of Smo inhibition on matrix metalloproteinases (MMP-2, MMP-9) and epithelial-mesenchymal transition (EMT).
• Employed a xenograft model to assess the in vivo efficacy of Smo inhibition using siRNA.

Main Results:

• Gli1 was detected in the nucleus of GBC cells but not normal cells, indicating pathway activation.
• Shh and Smo expression levels were significantly higher in GBC specimens compared to normal tissue.
• Exogenous Shh ligand enhanced GBC cell proliferation and invasiveness in vitro.
• Inhibition of Smo reduced GBC cell proliferation, invasiveness, MMP-2/MMP-9 expression, and EMT.
• Tumor growth was significantly suppressed in vivo in GBC xenografts treated with Smo siRNA.

Conclusions:

• Hh signaling is aberrantly activated in GBC and contributes to malignant phenotypes.
• Targeting Hh signaling, particularly Smo, demonstrates therapeutic potential for GBC treatment.
• Further research into Hh pathway inhibitors is warranted for developing novel GBC therapies.